Ross Feldman

Dr. Ross Feldman is Medical Director, Cardiac Sciences Program for the Winnipeg Regional Health Authority, in addition he is also Professor of Medicine at the University of Manitoba.

He was just recently the Chair of Medicine at Memorial University of Newfoundland, St. John’s Newfoundland & Labrador, Canada. He is the author of more than 200 original manuscripts, reviews and book chapters. His clinical research program centers on the development of new approaches to the management of hypertension and specifically the development of innovative strategies to improve blood pressure control.

A major focus of his efforts has been in the prevention and control of hypertension in Canada and specifically in the knowledge translation of optimal treatment approaches for hypertension management. Among past leadership positions, Dr. Feldman served as the first Chair of the Steering Committee of the Canadian Hypertension Education Program, the organization that since 1999 has produced, disseminated and implemented annually updated guidelines for management of hypertension. As well, he served as President of the Canadian Hypertension Society. He was also the founding President of Hypertension Canada- leading the process of integrating the efforts of the Canadian Hypertension Society, Canadian Hypertension Education Program and Blood Pressure Canada.

He has received a number of awards and scholarships in recognition of his contributions in research, teaching and for his efforts in the prevention and control of hypertension in Canada. These include the George Morris Piersol Research and Teaching Scholarship from the American College of Physicians, a Career Investigator Award from the Heart and Stroke Foundation of Ontario, the Burroughs-Wellcome Clinical Pharmacology Award and the Senior Investigator Award from the Canadian Society for Clinical Pharmacology as well as the Distinguished Service/Research Award of the Canadian Hypertension Society. He also the recipient of the George Fodor Award from Hypertension Canada for outstanding contributions to the prevention and control of hypertension.

Paul Knill

Paul Knill earned his law degree from Western University, and is a graduate of the Institute of Corporate Directors, Rotman School of Management.

Paul served as Managing Partner at the Canadian Law Firm, Siskinds LLP, during a period of significant expansion and change. His leadership encouraged innovative gathering and sharing of intellectual capital among business unit members. Paul went on to serve as an adjunct professor at Western University law school, and he currently contributes his corporate governance expertise by serving on the boards of a diverse number of Corporations.

Jeff Smith

Jeff has been the CEO at Alimentiv since October 2016. In May 2018, Jeff led the successful separation of the organization from its sole owner, Western University, to a Health Trust establishing the first social enterprise of its kind in North America.



Jeff has a strong record of leading high-performing global teams that support the growth of global business units. His background in clinical research spans more than 20 years in the pharma and contract research organization (CRO) industries. Prior to his current position, he held senior positions with Alimentiv (formerly Robarts Clinical Trials) including Vice President, Clinical Operations and Director, Business Development. And before joining Alimentiv he was a Senior Director, General Medicine & Vaccines/Infectious Disease with PharmaNet (now Syneos). Jeff trained as a registered nurse, and holds a Bachelor Degree in Health Sciences (nursing).



Jeff’s perspective on building a great company has been shaped from his experience working in a variety of ownership structures including government, private, public, private equity and venture capital. These experiences helped shape his vision for building a 100-year private company that pursues its purpose and putting people first ahead of shareholder returns. In May 2018, he was able to realize this vision with the transition of ownership of Robarts Clinical Trials to a Health Trust.



“When leaders prioritize goodness in themselves and in others, they can create lasting cultures and tremendous value.”